Ziltivekimab

Summary

Ziltivekimab (CHEMBL4297732) is a phase-3 clinical-stage antibody targeting FCGRT; indicated across 4 conditions including chronic kidney disease and anemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Targets: 1 (FCGRT)
• Indications: 4 conditions
• Clinical trials: 12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297732
Name	Ziltivekimab
Type	Antibody
Max phase	3

Also known as: Cor-001, COR-001, COR001, Medi 5117, Medi-5117, MEDI-5117, MEDI5117, NN-6018, NN6018, WBP-216, WBP216, Ziltivekimab

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
FCGRT	Fc fragment of IgG receptor and transporter	Binding	6.65	0%	P55899

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): FCGRT.

Dominant GO biological processes

GO term	Targets
IgG immunoglobulin transcytosis in epithelial cells mediated by FcRn immunoglobulin receptor	1
immune response	1

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
chronic kidney disease	1	MONDO:0005300	EFO:0003884
anemia	1	MONDO:0002280	EFO:0004272
rheumatoid arthritis	1	MONDO:0008383	EFO:0000685
nasopharyngeal neoplasm	1	MONDO:0005375	EFO:0004252

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE3	6
PHASE1	3
PHASE2	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05636176	PHASE3	RECRUITING	A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
NCT06118281	PHASE3	RECRUITING	ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06200207	PHASE3	RECRUITING	A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
NCT06263244	PHASE3	RECRUITING	Specifying the Anti-inflammatory Effects of Ziltivekimab
NCT07276282	PHASE3	RECRUITING	Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction
NCT07301034	PHASE3	RECRUITING	A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack
NCT02868229	PHASE1/PHASE2	COMPLETED	Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001
NCT03926117	PHASE2	COMPLETED	Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
NCT04626505	PHASE2	COMPLETED	Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.
NCT01559103	PHASE1	TERMINATED	Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients
NCT03126318	PHASE1	COMPLETED	A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001
NCT05379829	PHASE1	COMPLETED	A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).